Stemline Therapeutics Follows Verastem's Lead, Files for IPO
By Marie Powers
Wednesday, April 4, 2012
Following the lead of Verastem Inc., which raised $55 million earlier this year in its initial public offering (IPO), New York-based Stemline Therapeutics Inc. filed an S-1 registration statement with the SEC for an IPO, seeking $50 million to advance its cancer stem cell therapeutics.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.